American pharmaceutical companies are facing a wave of protest from investors. AbbVie, Eli Lilly, Gilead, Johnson & Johnson, Merck and Pfizer are targeted by a shareholder engagement campaign to improve access to medicines and reduce costs. A common practice of laboratories is particularly targeted, that of the extension of the duration of patents which allows a company to keep the marketing of a drug for itself, and therefore to set the price, for which two resolutions have been filed. at the general meetings of AbbVie and Eli Lilly.
The post Big Pharma: investors want to act on drug prices first appeared on Interfaith Center on Corporate Responsibility.